Shandong Shenglu Pharmaceutical Co., Ltd.

Potassium is the main cation in cells, with a concentration of 150-160 mmol/L, while the main cation outside cells is sodium ions, and the serum potassium concentration is only 3.5-5.0 mmol/L. The body mainly relies on Na-KATPase on the cell membrane to maintain the difference in K and Na concentrations inside and outside cells. The acid-base balance in the body has an impact on potassium metabolism. For example, when acidosis occurs, H enters the cell. In order to maintain the potential difference inside and outside the cell, K is released outside the cell, causing or aggravating hyperkalemia. Metabolic disorders can also affect acid-base balance. The normal potassium ion concentration and concentration difference inside and outside the cell are closely related to certain functions of the cell, such as carbohydrate metabolism, glycogen storage and protein metabolism, nerves, muscles including the excitability and conductivity of the myocardium, etc.

After passing through the blood-cerebrospinal fluid barrier, it is decomposed into glutamate and gamma-aminobutyric acid (GABA). Glutamate is involved in the information transmission of the central nervous system. Gamma-aminobutyric acid can antagonize the excitotoxic effects of glutamate, improve nerve cell metabolism, maintain nerve stress resistance, reduce the effect of blood ammonia, and improve brain function.

It has a significant effect of increasing the number of peripheral blood leukocytes in normal rabbits. The peak of the leukocyte count occurs on the 4th day after the first administration, which is 72% higher than before the administration, which is better than the leukocyte-raising drug shark liver alcohol. It has a significant effect of increasing leukocytes in rabbits with leukopenia caused by cobalt 60-gamma ray and deep X-ray irradiation. It also has a preventive effect on leukopenia when administered two days before irradiation. It can also prevent leukopenia in mice caused by mitomycin C. It has a synergistic inhibitory effect on the solid type of Ehrlich carcinoma when used in combination with cyclophosphamide, and the toxicity of leukopenia caused by cyclophosphamide is significantly reduced.

It has a significant effect on increasing the number of peripheral blood leukocytes in normal rabbits. The peak value of leukocyte count occurs on the 4th day after the first administration, which is 72% higher than that before administration, which is better than the leukocyte-increasing drug shark liver alcohol. It has a significant effect on increasing leukocytes in rabbits induced by cobalt 60-gamma ray and deep X-ray irradiation. It also has a preventive effect on leukocyte decrease when administered two days before irradiation. It can prevent leukopenia in mice caused by mitomycin C. It has a synergistic inhibitory effect on the solid type of Ehrlich carcinoma when used in combination with cyclophosphamide, and can reduce the toxicity of cyclophosphamide-induced leukopenia.

This product is a procoagulant that competitively inhibits the adsorption of plasminogen on the fibrin network, reduces its activation level, and protects fibrin from being degraded by plasmin, thereby achieving a hemostatic effect.

This product is a selective 5-HT3 receptor antagonist. Its mechanism of action may be to antagonize the 5-HT3 receptors in the peripheral vagus nerve endings and central chemoreceptor areas, thereby blocking the vomiting reflex caused by factors such as chemotherapy and surgery that promote the release of 5-HT from intestinal chromaffin cells and excite the vagus afferent nerves. This product has high selectivity and no side effects such as extrapyramidal reactions and excessive sedation.